Dermata Short Long Term Debt from 2010 to 2024
| DRMA Stock | USD 1.15 0.01 0.86% |
Short and Long Term Debt | First Reported 2010-12-31 | Previous Quarter 4.1 M | Current Value 2.4 M | Quarterly Volatility 1.4 M |
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 213.6 K, Depreciation And Amortization of 8.4 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.29. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
Dermata | Short Long Term Debt |
Latest Dermata Therapeutics' Short Long Term Debt Growth Pattern
Below is the plot of the Short Long Term Debt of Dermata Therapeutics over the last few years. It is the total of a company's short-term and long-term borrowings. Dermata Therapeutics' Short and Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Short Long Term Debt | 10 Years Trend |
|
Short Long Term Debt |
| Timeline |
Dermata Short Long Term Debt Regression Statistics
| Arithmetic Mean | 1,624,785 | |
| Geometric Mean | 1,214,764 | |
| Coefficient Of Variation | 83.24 | |
| Mean Deviation | 1,192,317 | |
| Median | 730,547 | |
| Standard Deviation | 1,352,513 | |
| Sample Variance | 1.8T | |
| Range | 3.3M | |
| R-Value | 0.77 | |
| Mean Square Error | 801.7B | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | 232,901 | |
| Total Sum of Squares | 25.6T |
Dermata Short Long Term Debt History
Other Fundumenentals of Dermata Therapeutics
Dermata Therapeutics Short Long Term Debt component correlations
Click cells to compare fundamentals
About Dermata Therapeutics Financial Statements
Dermata Therapeutics stakeholders use historical fundamental indicators, such as Dermata Therapeutics' Short Long Term Debt, to determine how well the company is positioned to perform in the future. Although Dermata Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Dermata Therapeutics' assets and liabilities are reflected in the revenues and expenses on Dermata Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 4.1 M | 2.7 M | |
| Short and Long Term Debt | 4.1 M | 2.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out the analysis of Dermata Therapeutics Correlation against competitors. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.35) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.